GLAS Glass House Brands (GLAS) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0001848731
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
51
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · no price filed
What the filings say about GLAS
Insiders, 180 days
-$30.7K net sold
1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: purchase, 2024-11-26
Planned sales (Form 144), 90 days
$416.0K
1 notice
Glass House Brands insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Glass House Brands Inc. insiders sold a net $30.7K of stock across 1 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Canadian issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.9% of the 3,783 shares held after it.
- No other insider sold within 30 days.
- 51 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, Corporate Controller Tu William sold about $30.7K of GLAS on Sep 11, 2026, the largest insider sale at the company on our record; 51 funds added in the latest 13F quarter.1 transaction on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$30.7K over 180 days
-$30.7K over 90 days
more than 59% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
51 funds bought in last quarter
below 52% of Pharma & Biotech
Revenue
-9.4% year over year
below 65% of Pharma & Biotech
Margin
-16.3% net margin
more than 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.5% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch GLAS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
Who owns GLAS: institutional holders (13F)
13F holdings, latest reported quarter
5,182,030 sh
$67.4M
2,728,768 sh
$35.0M
2,700,000 sh
$33.3M
2,283,439 sh
$29.7M
1,145,088 sh
$14.9M
Congress trades in GLAS
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2024-11-26 · disclosed 9 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GLAS planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Kyle Kazan
Filed 2026-08-28
$416.0K
GLAS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
AdvisorShares Pure Cannabis ETF
$1.3M position · as of 2026-06-30
3.8%
AdvisorShares Pure US Cannabis ETF
$9.8M position · as of 2026-06-30
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $30.7K sold by insiders over 180 days, 51 funds added last quarter, $416.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
GLAS financials
Revenue growth
-9.4%
XBRL, annual
Net margin
-16.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
Free cash flow, TTM GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Single quarter
Debt to equity
0.93x
long-term 2025-12-31 plus current 2025-12-31; equity 2025-12-31
Debt to equity GLAS
| FY Dec 2025 | 0.93x |
| FY Dec 2024 | 0.50x |
| FY Dec 2023 | 0.71x |
| FY Dec 2022 | 0.37x |
| FY Dec 2021 | 0.25x |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
Cash flow to debt GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no close on file at or before the as-of date
Enterprise value GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no close on file at or before the as-of date
FCF yield GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing GLAS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| none filed |
At each fiscal year end
Trailing four quarters at each quarter end
Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $182.0M | $200.9M | $160.8M | $90.9M |
| Gross profit | $77.0M | $97.4M | $81.0M | $20.7M |
| Operating income | -$16.5M | $5.7M | -$49.5M | -$56.4M |
| Net income | -$29.7M | $519.0K | -$98.3M | -$32.9M |
| EPS (diluted) | -0.55 | -0.21 | -1.62 | -0.83 |
| Operating cash flow | $11.4M | $28.4M | $23.2M | -$40.8M |
| Long-term debt | $68.6M | $50.6M | $56.5M | $62.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
GLAS Stock Sonar score 5/7 axes
Find similar shapesCompareGLAS ranks highest on risk and compliance (86th percentile) and institutional and government (48th), and lowest on financial health (20th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
GLAS filings, in plain words
Are Glass House Brands insiders buying or selling GLAS?
In the 180 days to 2026-10-28, Glass House Brands insiders were net sellers, a net $30.7K across purchases and sales reported on Form 4, by 1 seller.
Have members of Congress traded GLAS?
Yes, but not in the year to 2026-10-28; the latest on record is a purchase by Max Miller dated 2024-11-26.
Are there planned insider sales of GLAS?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $416.0K of stock; the latest, by Kyle Kazan, was filed 2026-08-28.
Read the full summary
In the 180 days to 2026-10-28, Glass House Brands insiders were net sellers of GLAS, a net $30.7K across purchases and sales reported on Form 4 by 1 seller. Members of Congress have disclosed trades in GLAS, none in the last year; the latest on record is a purchase by Max Miller dated 2024-11-26. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $416.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
